Loading...
XNAS
BCRX
Market cap2.19bUSD
Jul 10, Last price  
10.45USD
1D
-3.51%
1Q
12.13%
Jan 2017
69.35%
Name

BioCryst Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:BCRX chart
P/E
8.31
P/S
2.51
EPS
1.26
Div Yield, %
—
Shrs. gr., 5y
5.50%
Rev. gr., 5y
117.89%
Revenues
875m
+94.10%
6,211,93671,237,90156,561,36974,589,00063,501,00019,643,00026,293,00017,331,00013,608,00048,257,00026,353,00025,186,00020,653,00048,835,00017,812,000157,170,000270,827,000331,412,000450,712,000874,837,000
Net income
264m
P
-43,617,853-29,055,524-24,731,570-13,452,000-32,733,000-56,948,000-39,081,000-30,108,000-45,189,000-43,019,000-55,144,000-65,782,000-101,252,000-108,897,000-182,814,000-184,062,000-247,116,000-226,539,000-88,881,000263,861,000
CFO
330m
P
-15,211,315-24,997,799-20,873,820-16,218,470-28,554,221-32,251,000-37,397,000-26,530,000-38,551,000-13,116,000-53,438,000-41,143,000-92,565,000-89,584,000-137,216,000-142,157,000-161,850,000-95,141,000-52,020,000329,880,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
URL
https://www.biocryst.com/
IPO date
Mar 04, 1994
Employees
531
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT